HC
ROIV icon

Hurley Capital’s Roivant Sciences ROIV Stock Holding History

Hurley Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.71K Buy
+206
New +$5.29K ﹤0.01% 405
2025
Q4 		– Sell
-413
Closed -$6.25K – 728
2025
Q3 		$6.25K Buy
+413
New +$5.11K ﹤0.01% 412

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hurley Capital's ROIV Position: Q1 2026 in Review

Hurley Capital opened a new position in Roivant Sciences (ROIV) in Q1 2026: 206 shares worth $5.71K. The stake represents ﹤0.01% of the portfolio and ranks #405 among its holdings. This is a return to the name: Hurley Capital previously reported a position in ROIV as recently as Q3 2025.

Hurley Capital first reported a position in ROIV in Q3 2025 and has held it in 2 quarters since. The position peaked at $6.25K in Q3 2025. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Hurley Capital held 206 shares of Roivant Sciences worth $5.71K as of Q1 2026.
  • Roivant Sciences was a new Hurley Capital position in Q1 2026.
  • Roivant Sciences made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #405 holding.
  • Hurley Capital first reported a position in Roivant Sciences in Q3 2025 and has held it in 2 quarters since.
  • Hurley Capital's Roivant Sciences position peaked at $6.25K in Q3 2025.
  • 440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.